M&A Deal Summary

Pacira Pharmaceuticals Acquires MyoScience

On March 5, 2019, Pacira Pharmaceuticals, Inc. acquired medical products company MyoScience, Inc. from NMT Capital (Nexus) for 220M USD

Acquisition Highlights
  • This is Pacira Pharmaceuticals’ 1st transaction in the Medical Products sector.
  • This is Pacira Pharmaceuticals’ 1st largest (disclosed) transaction.
  • This is Pacira Pharmaceuticals’ 1st transaction in the United States.
  • This is Pacira Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary

Date 2019-03-05
Target MyoScience, Inc.
Sector Medical Products
Buyer(s) Pacira Pharmaceuticals, Inc.
Sellers(s) NMT Capital (Nexus)
Deal Type Add-on Acquisition
Deal Value 220M USD
Advisor(s) Perella Weinberg Partners (Financial)
Latham & Watkins (Legal)

Target

MyoScience, Inc.

Fremont, California, United States
website
MyoScience, Inc. is a medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. MyoScience, Inc. was founded in 2005 and is based in Fremont, California.

Search 163,065 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pacira Pharmaceuticals, Inc.

Parsippany, New Jersey, United States

website


Category Company
Founded 2006
SectorLife Science
Employees624
Revenue 430M USD (2020)
DESCRIPTION

Pacira is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. Pacira’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension). EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Pacira was founded in 2006 and is based in Parsippany, New Jersey.


DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 2
State (California) 1 of 1
Country (United States) 1 of 2
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-11 Flexion Therapeutics, Inc.

Burlington, Massachusetts, United States

Flexion Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis (OA), postsurgical pain and low back pain. Flexion Therapeutics is based in Burlington, Massachusetts.

Buy -

Seller(S) 1

SELLER

NMT Capital (Nexus)

Quincy, Massachusetts, United States

website


Category Private Equity Firm
SizeSmall
Type Sector Agnostic
DESCRIPTION

NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.


DEAL STATS #
Overall 8 of 8
Sector (Medical Products) 3 of 3
Type (Add-on Acquisition) 7 of 7
State (California) 2 of 2
Country (United States) 7 of 7
Year (2019) 1 of 1
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 Magellan Biosciences, Inc.

Chelmsford, Massachusetts, United States

Magellan Biosciences, Inc. is a developer and manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.

Sell -